Roquette Launches New Excipient For Taste-Masking

Suitable for many oral dosage forms, KLEPTOSE LINECAPS is ideal for paediatric and nutraceutical use.

API’s undesirable taste is one of the most challenging parameters when addressing patient compliance for oral drug delivery systems. This issue is even more critical in the case of pediatric and geriatric populations. The ability to mask taste impacts the commercial success of the final product by increasing patient compliance and business profitability.

 

To address this issue, Roquette Pharma has developed KLEPTOSE LINECAPS 17, a new excipient for taste-masking.

 

This particular maltodextrin contains linear amylose in significant amounts, making it easy to form the inclusion compounds with API’s, flavours or nutraceutical ingredients needed for taste-masking.  

 

As soluble amylose it is a realistic alternative for both food and pharmaceutical preparations.

 

KLEPTOSE LINECAPS 17 also serves as a flavour encapsulation matrix, protecting against oxidation and preserving original flavours.

 

KLEPTOSE LINECAPS 17 is suitable for many oral dosage forms, e.g. liquid and solid formulations intended for liquid reconstitution. Its food grade acceptability is particularly appropriate for the paediatric and nutraceutical markets.